Brokers Issue Forecasts for Adagene FY2029 Earnings

Adagene Inc. (NASDAQ:ADAGFree Report) – Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Adagene in a research note issued to investors on Monday, January 27th. HC Wainwright analyst A. He anticipates that the company will post earnings of ($0.56) per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Adagene’s current full-year earnings is ($0.65) per share.

Adagene Stock Down 1.1 %

Shares of ADAG stock opened at $1.85 on Tuesday. The business’s fifty day moving average is $2.03 and its 200 day moving average is $2.39. Adagene has a twelve month low of $1.74 and a twelve month high of $3.89.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Catalina Capital Group LLC grew its position in shares of Adagene by 129.2% during the fourth quarter. Catalina Capital Group LLC now owns 29,198 shares of the company’s stock worth $58,000 after purchasing an additional 16,461 shares in the last quarter. Mill Creek Capital Advisors LLC bought a new stake in shares of Adagene in the 3rd quarter valued at approximately $202,000. Finally, Exome Asset Management LLC lifted its stake in shares of Adagene by 74.1% in the 3rd quarter. Exome Asset Management LLC now owns 262,625 shares of the company’s stock valued at $583,000 after purchasing an additional 111,749 shares during the last quarter. Institutional investors own 9.51% of the company’s stock.

Adagene Company Profile

(Get Free Report)

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.

Further Reading

Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.